Headlines about Madrigal Pharmaceuticals (NASDAQ:MDGL) have trended somewhat positive this week, according to Accern. The research group identifies negative and positive media coverage by reviewing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Madrigal Pharmaceuticals earned a coverage optimism score of 0.12 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 45.9555764736122 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the next several days.
These are some of the news articles that may have impacted Accern’s scoring:
Several research firms have recently commented on MDGL. HC Wainwright upped their target price on Madrigal Pharmaceuticals from $105.00 to $156.00 and gave the company a “buy” rating in a research report on Tuesday. Zacks Investment Research downgraded Madrigal Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday. Roth Capital set a $82.00 price target on Madrigal Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, November 30th. BidaskClub raised Madrigal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, January 20th. Finally, JMP Securities raised their target price on Madrigal Pharmaceuticals from $40.00 to $63.00 and gave the company an “outperform” rating in a report on Friday, October 13th. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The stock has a consensus rating of “Buy” and a consensus target price of $139.20.
Shares of Madrigal Pharmaceuticals (MDGL) traded down $1.05 on Friday, hitting $147.99. The stock had a trading volume of 323,310 shares, compared to its average volume of 209,472. Madrigal Pharmaceuticals has a one year low of $13.09 and a one year high of $152.62. The company has a market cap of $2,070.00, a PE ratio of -60.16 and a beta of 1.19.
Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its earnings results on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.79) by $0.11. research analysts predict that Madrigal Pharmaceuticals will post -2.57 EPS for the current year.
WARNING: This report was originally reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this report on another publication, it was illegally stolen and republished in violation of U.S. & international copyright legislation. The original version of this report can be read at https://www.dispatchtribunal.com/2018/02/02/madrigal-pharmaceuticals-mdgl-given-daily-coverage-optimism-rating-of-0-12.html.
Madrigal Pharmaceuticals Company Profile
Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).
Receive News & Ratings for Madrigal Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.